DEA seeks to reclassify marijuana, allow prescriptions for first time: Reports

The federal government is poised to no longer consider marijuana among the most dangerous and addictive substances, according to reports about a proposed plan from the Drug Enforcement Administration.

In what would be the biggest change in marijuana policy the federal government has taken since pot was first outlawed, the Drug Enforcement Administration will be taking public comments on a plan to recategorize marijuana under the Controlled Substances Act, according to reporting by the Associated Press and NBC News. The outlets cite anonymous sources with knowledge of the plans.

The plan wouldn't legalize marijuana at the federal level outright, but it would reclassify it from a Schedule I drug – believed highly dangerous, addictive and without medical use – to a Schedule III drug that can be lawfully prescribed as medication. Marijuana has been a Schedule I drug since the Controlled Substances Act was signed in 1970.

This bureaucratic move is only a small step toward what advocates hope will be full legalization of the drug. However, the new proposed classification does not fully address the inconsistencies between federal restrictions and the laws in a growing number of states that have authorized medical and recreational use of pot.

Twenty-four states and Washington, D.C., have legalized the recreational use of marijuana, and 14 other states authorize it for medical use, according to the Pew Research Center.

The federal proposal to reschedule marijuana would have broad support among voters. A nationwide survey last fall commissioned by the Coalition for Cannabis Rescheduling Reform found nearly 60% of likely voters supported rescheduling, with 65% of younger voters 18 to 25 favoring it, the highest of any demographic group polled. Overall, the number of Americans who think marijuana should be legal reached a record-high at 70%, according to a Gallup poll in the fall.

For decades, marijuana has been listed under the Controlled Substances Act as a Schedule I drug, alongside heroin, LSD and ecstasy. The act categorizes drugs based on their potential for abuse, addiction and medical use. Schedule I drugs are outlawed under federal law level and deemed to be without accepted medical use.

In 2022, President Joe Biden directed the Department of Health and Human Services to conduct a review of how marijuana is classified; and last year HHS recommended it be rescheduled to Schedule III, alongside drugs like Tylenol with codeine and anabolic steroids.

The latest news is the culmination of that effort, with the agency that oversees how law enforcement treats drugs aligning with the HHS recommendation.

The DEA's decision will be followed by a 60-day public review period. It was not immediately clear when the proposed rule would be open to public comment. The rule needs to be approved by the White House Office of Management and Budget, AP reported.

Experts previously told USA TODAY that marijuana’s placement on Schedule I was not based on credible scientific evidence of its perils, but once it was listed, researchers and advocates faced a heavy burden trying to prove it shouldn’t face such stiff restrictions.

What exactly does rescheduling cannabis mean?

Placing marijuana in Schedule III puts it on par with drugs, such as ketamine, testosterone, anabolic steroids or Tylenol with codeine, that have “moderate to low potential for physical and psychological dependence,” according to the DEA.

Schedule III drugs can be legally prescribed by licensed health care providers and dispensed by licensed pharmacies. Rescheduling could also help resolve a massive federal tax burden that has been placed on cannabis companies – which were effectively seen as drug traffickers for tax purposes.

But rescheduling marijuana doesn’t make it legal to use recreationally, and it doesn’t change much about current state cannabis programs, said Jay Wexler, who teaches a seminar about marijuana laws at Boston University. It would still a controlled substance even with the DEA's announcement

Wexler and other policy experts and advocates say rescheduling is not a solution, but it could be a sign the federal government is catching up with public opinion and consensus in the medical field that there are therapeutic benefits to marijuana, along with some risks.

"Rescheduling is a step forward, but it is not nearly enough. And there's no reason to keep cannabis in the Controlled Substances Act,” Wexler told USA TODAY ahead of the DEA announcement.

What are the possible risks of marijuana?

Because of its classification, marijuana has been hard to study. But the decision to reschedule marijuana is due in large part to its lower public health risk, federal scientists have said.

In a leaked HHS document, officials wrote to the DEA to support lowering its classification to Schedule III. Its risk for addiction was lower than other drugs and it had medical benefits, unlike Schedule I and II drugs, HHS researchers said.

Still, scientists said, users develop moderate to low physical dependence on it, and there is some risk of psychological dependence. However, they noted, the withdrawal symptoms are “relatively mild” compared with alcohol. Marijuana is more comparable to tobacco, they said.

There are no known deaths from a marijuana overdose, according to the National Institute on Drug Abuse, or NIDA. But it does affect physical and mental health.

Marijuana can cause permanent IQ loss for people who begin using it at a young age, the institute said. Additionally, long-term use has been associated with temporary paranoia and hallucinations, and it can exacerbate symptoms with disorders such as schizophrenia, NIDA said.

Marijuana smoke has a similar health impact to tobacco smoke. NIDA found people who smoke marijuana frequently develop issues with breathing, akin to tobacco smokers.

Smoking cannabis, the most common way to consume the drug, may have additional risks because of particulate matter a person inhales, according to a recent study in the Journal of the American Heart Association. Researchers noted cannabis smoke isn’t all that different than tobacco smoke, the only difference being the added effect of the psychoactive drug THC in marijuana rather than nicotine in tobacco.

Respiratory issues include daily cough, phlegm and a higher risk of lung infections, however, the institute said it’s unclear if marijuana causes a greater risk of lung cancer.

Smoking marijuana also increases heart rate, which can increase the chance of heart attack, especially among older people and people with heart conditions. The heart association journal study linked increased cannabis use with an increased risk of heart attack and stroke.

“Despite common use, little is known about the risks of cannabis use and, in particular, the cardiovascular disease risks,” the study’s lead author, Abra Jeffers, a data analyst at Boston’s Massachusetts General Hospital, said in a statement. “The perceptions of the harmfulness of smoking cannabis are decreasing, and people have not considered cannabis use dangerous to their health. However, previous research suggested that cannabis could be associated with cardiovascular disease.” She noted that smoking cannabis, which is the predominant way it is used, could pose other risks because it involves inhaling particulate matter.

In the study published in late February, researchers examined Centers for Disease Control and Prevention survey data of over 400,000 adults from 2016 to 2020, looking at self-reported cannabis use with cardiovascular outcomes, such as heart disease, heart attacks and strokes.

People who used marijuana daily had a 25% higher chance of having a heart attack and a 42% higher chance of stroke than those who didn’t use it at all.

Proposal reflects potential for health benefits

The cannabis plant has been used for medicinal purposes for centuries, if not millennia. It appears to help with treating pain, insomnia, anxiety, and glaucoma, among other health conditions. Still, evidence is mixed and more research into its health benefits is needed, researchers at Johns Hopkins Bloomberg School of Public Health said in August.

While the FDA hasn’t approved the cannabis plant for any medical use, federal regulators have approved several drugs containing cannabinoids, or substances such as THC or CBD found in the cannabis plant, according to the National Institutes of Health.

These include Epidiolex, a purified form of CBD ingested orally, that is FDA-approved to treat seizures associated with two severe forms of epilepsy. Marinol and Syndros both contain synthetic THC and are used to treat nausea and vomiting caused by chemotherapy. Nabilone, another synthetic similar to THC, is approved as the brand name drug Cesamet for people with HIV/AIDS who experiencing weight loss and appetite loss.

A 2017 federal report found cannabis or cannabinoids were more likely to reduce pain symptoms for patients with chronic pain. Additionally, there is some evidence that cannabis is effective in treating symptoms of multiple sclerosis, particularly addressing the stiff or rigid muscles caused by the disease. One cannabinoid drug, nabiximol, a mouth spray that has both THC and CBD, has been approved in several countries but not in the U.S. Under the brand name Sativex, it has shown pain relief for people with cancer or multiple sclerosis.

Other research has examined cannabis’ uses to treat post-traumatic stress disorder, but the NIH said the evidence is mixed.

This article originally appeared on USA TODAY: DEA seeks to reclassify marijuana, allow prescriptions: Reports